{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T16:30:35Z","timestamp":1794933035396,"version":"4.9.1"},"reference-count":137,"publisher":"Archives of Endocrinology and Metabolism","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,7]]},"DOI":"10.20945\/2359-4292-2023-0123","type":"journal-article","created":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T14:33:42Z","timestamp":1701959622000},"source":"Crossref","is-referenced-by-count":31,"title":["Brazilian evidence-based guideline for screening, diagnosis, treatment, and follow-up of metabolic dysfunction-associated steatotic liver disease (MASLD) in adult individuals with overweight or obesity: A joint position statement from the Brazilian Society of Endocrinology and Metabolism (SBEM), Brazilian Society of Hepatology (SBH), and Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso)"],"prefix":"10.20945","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1561-2926","authenticated-orcid":false,"given":"Rodrigo Oliveira","family":"Moreira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2292-1735","authenticated-orcid":false,"given":"Cynthia Melissa","family":"Valerio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1355-2368","authenticated-orcid":false,"given":"Cristiane Alves","family":"Villela-Nogueira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6181-4951","authenticated-orcid":false,"given":"Cintia","family":"Cercato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5873-9498","authenticated-orcid":false,"given":"Fernando","family":"Gerchman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0598-5529","authenticated-orcid":false,"given":"Ana Maria Pita","family":"Lottenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9089-9889","authenticated-orcid":false,"given":"Am\u00e9lio Fernando","family":"Godoy-Matos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7274-6843","authenticated-orcid":false,"given":"Ricardo de Andrade","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8965-6556","authenticated-orcid":false,"given":"Carlos Eduardo Brand\u00e3o","family":"Mello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5001-246X","authenticated-orcid":false,"given":"M\u00e1rio Reis","family":"\u00c1lvares-da-Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9066-0405","authenticated-orcid":false,"given":"Nathalie Carvalho","family":"Leite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7698-6919","authenticated-orcid":false,"given":"Helma Pinchemel","family":"Cotrim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4890-9259","authenticated-orcid":false,"given":"Edison Roberto","family":"Parisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6129-7045","authenticated-orcid":false,"given":"Giovanni Faria","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5433-3386","authenticated-orcid":false,"given":"Paulo Augusto Carvalho","family":"Miranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0973-5065","authenticated-orcid":false,"given":"Bruno","family":"Halpern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2848-417X","authenticated-orcid":false,"given":"Claudia Pinto","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"8510","reference":[{"issue":"1","key":"key20231207093321_B1","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/hep.29721","article-title":"Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis","volume":"68","author":"Younossi","year":"2018","unstructured":"1 Younossi ZM, Loomba R, Anstee QM, Rinella ME, Bugianesi E, Marchesini G, et al. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis. Hepatology. 2018;68(1):349-60. doi: 10.1002\/hep.29721","journal-title":"Hepatology"},{"issue":"6","key":"key20231207093321_B2","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease","volume":"64","author":"European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO).","year":"2016","unstructured":"2 European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388-402. doi:10.1016\/j.jhep.2015.11.004","journal-title":"J Hepatol"},{"issue":"5","key":"key20231207093321_B3","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/hep.31173","article-title":"Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of NAFLD","volume":"72","author":"Paik","year":"2020","unstructured":"3 Paik JM, Golabi P, Younossi Y, Mishra A, Younossi ZM. Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of NAFLD. Hepatology. 2020;72(5):1605-16. doi: 10.1002\/hep.31173","journal-title":"Hepatology"},{"issue":"6","key":"key20231207093321_B4","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.aohep.2020.09.006","article-title":"Latin American Association for the study of the liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease","volume":"19","author":"Arab","year":"2020","unstructured":"4 Arab JP, Dirchwolf M, Alvares-da-Silva MR, Barrera F, Benitez C, Castellanos-Fernandez M, et al. Latin American Association for the study of the liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease. Ann Hepatol. 2020;19(6):674-90. doi: 10.1016\/j.aohep.2020.09.006","journal-title":"Ann Hepatol"},{"issue":"10290","key":"key20231207093321_B5","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease","volume":"397","author":"Powell","year":"2021","unstructured":"5 Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet. 2021;397(10290):2212-24. doi: 10.1016\/S0140-6736(20)32511-3","journal-title":"Lancet"},{"key":"key20231207093321_B6","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.metabol.2018.11.014","article-title":"Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics","volume":"92","author":"Polyzos","year":"2019","unstructured":"6 Polyzos SA, Kountouras J, Mantzoros CS. Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. Metabolism. 2019;92:82-97. doi: 10.1016\/j.metabol.2018.11.014","journal-title":"Metabolism"},{"issue":"4","key":"key20231207093321_B7","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","unstructured":"7 Younossi ZM, Golabi P, de Avila L, Paik JM, Srishord M, Fukui N, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. J Hepatol. 2019;71(4):793-801. doi: 10.1016\/j.jhep.2019.06.021","journal-title":"J Hepatol"},{"issue":"2","key":"key20231207093321_B8","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease","volume":"149","author":"Angulo","year":"2015","unstructured":"8 Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149(2):389-97.e10. doi: 10.1053\/j.gastro.2015.04.043","journal-title":"Gastroenterology"},{"issue":"5","key":"key20231207093321_B9","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/hep.27368","article-title":"Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up","volume":"61","author":"Ekstedt","year":"2015","unstructured":"9 Ekstedt M, Hagstrom H, Nasr P, Fredrikson M, Stal P, Kechagias S, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015;61(5):1547-54. doi: 10.1002\/hep.27368","journal-title":"Hepatology"},{"issue":"10","key":"key20231207093321_B10","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.12565","article-title":"Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease","volume":"2","author":"Kleiner","year":"2019","unstructured":"10 Kleiner DE, Brunt EM, Wilson LA, Behling C, Guy C, Contos M, et al. Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease. JAMA Netw Open. 2019;2(10):e1912565. doi: 10.1001\/jamanetworkopen.2019.12565","journal-title":"JAMA Netw Open"},{"issue":"1","key":"key20231207093321_B11","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement","volume":"73","author":"Eslam","year":"2020","unstructured":"11 Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomes M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol 2020;73(1):202-9. doi: 10.1016\/j.jhep.2020.03.039.","journal-title":"J Hepatol"},{"issue":"23","key":"key20231207093321_B12","first-page":"05080","article-title":"99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical","volume":"S0168-8278","author":"Hagstrom","year":"2023","unstructured":"12 Hagstrom H, Vessby J, Eksted M, Shang Y. 99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical. J Hepatol. 2023;S0168-8278(23)05080-8. doi: 10.1016\/j.jhep.2023.08.026.","journal-title":"J Hepatol"},{"issue":"6 Suppl 1","key":"key20231207093321_B13","first-page":"1","article-title":"[Diretriz brasileira baseada em evid\u00eancias sobre preven\u00e7\u00e3o de doen\u00e7as cardiovasculares em pacientes com diabetes: posicionamento da Sociedade Brasileira de Diabetes (SBD) da Sociedade Brasileira de Cardiologia (SBC) e da Sociedade Brasileira de Endocrinologia e Metabologia (SBEM)]","volume":"109","author":"Faludi","year":"2017","unstructured":"13 Faludi AA, Izar MCO, Saraiva JFK, Bianco HT, Chacra APM, Bertoluci MC, et al. [Diretriz brasileira baseada em evid\u00eancias sobre preven\u00e7\u00e3o de doen\u00e7as cardiovasculares em pacientes com diabetes: posicionamento da Sociedade Brasileira de Diabetes (SBD), da Sociedade Brasileira de Cardiologia (SBC) e da Sociedade Brasileira de Endocrinologia e Metabologia (SBEM)]. Arq Bras Cardiol. 2017;109(6 Suppl 1):1-31. doi: 10.5935\/abc.20170188","journal-title":"Arq Bras Cardiol"},{"issue":"16 Suppl 2","key":"key20231207093321_B14","first-page":"S358","article-title":"Part 2: Evidence Evaluation and Guidelines Development: 2020 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care","volume":"142","author":"Magid","year":"2020","unstructured":"14 Magid DJ, Aziz K, Cheng A, Hazinski MF, Hoover AV, Mahgoub M, et al. Part 2: Evidence Evaluation and Guidelines Development: 2020 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2020;142(16 Suppl 2):S358-65. doi: 10.1161\/CIR.0000000000000898","journal-title":"Circulation"},{"issue":"5","key":"key20231207093321_B15","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22052350","article-title":"Treatments for NAFLD: State of Art","volume":"22","author":"Mantovani","year":"2021","unstructured":"15 Mantovani A, Dalbeni A. Treatments for NAFLD: State of Art. Int J Mol Sci. 2021;22(5). doi: 10.3390\/ijms22052350","journal-title":"Int J Mol Sci"},{"issue":"4","key":"key20231207093321_B16","doi-asserted-by":"crossref","DOI":"10.1002\/edm2.113","article-title":"The regulatory state of nonalcoholic steatohepatitis and metabolism","volume":"3","author":"Omokaro","year":"2020","unstructured":"16 Omokaro SO, Golden JK. The regulatory state of nonalcoholic steatohepatitis and metabolism. Endocrinol Diabetes Metab. 2020;3(4):e00113. doi: 10.1002\/edm2.113","journal-title":"Endocrinol Diabetes Metab"},{"key":"key20231207093321_B17","article-title":"Noncirrhotic nonalcoholic steatohepatitis with liver fibrosis: Developing drugs for treatment","author":"Center for Drug Evaluation and Research (CDER)","year":"2018  31, 2019","unstructured":"17 Center for Drug Evaluation and Research (CDER). Noncirrhotic nonalcoholic steatohepatitis with liver fibrosis: Developing drugs for treatment. Guidance for Industry. 2018 July 31st, 2019. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/noncirrhoticnonalcoholic-steatohepatitis-liver-fibrosis-developing-drugs-treatment.","journal-title":"Guidance for Industry"},{"issue":"17","key":"key20231207093321_B18","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","article-title":"Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease","volume":"385","author":"Sanyal","year":"2021","unstructured":"18 Sanyal AJ, Van Natta ML, Clark J, Neuschwander-Tetri BA, Diehl A, Dasarathy S, et al. Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease. N Engl J Med. 2021;385(17):1559-69. doi: 10.1056\/NEJMoa2029349","journal-title":"N Engl J Med"},{"issue":"8","key":"key20231207093321_B19","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/ajg.2016.178","article-title":"Metabolically Healthy Obesity and the Development of Nonalcoholic Fatty Liver Disease","volume":"111","author":"Chang","year":"2016","unstructured":"19 Chang Y, Jung HS, Cho J, Zhang Y, Yun KE, Lazo M, et al. Metabolically Healthy Obesity and the Development of Nonalcoholic Fatty Liver Disease. Am J Gastroenterol. 2016;111(8):1133-40. doi: 10.1038\/ajg.2016.178","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"key20231207093321_B20","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1111\/liv.14184","article-title":"Metabolically healthy versus unhealthy obesity and risk of fibrosis progression in non-alcoholic fatty liver disease","volume":"39","author":"Kim","year":"2019","unstructured":"20 Kim Y, Chang Y, Cho YK, Ahn J, Shin H, Ryu S. Metabolically healthy versus unhealthy obesity and risk of fibrosis progression in non-alcoholic fatty liver disease. Liver Int. 2019;39(10):1884-94. doi: 10.1111\/liv.14184","journal-title":"Liver Int"},{"issue":"4","key":"key20231207093321_B21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003100","article-title":"Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies","volume":"17","author":"Jarvis","year":"2020","unstructured":"21 Jarvis H, Craig D, Barker R, Spiers G, Stow D, Anstee QM, et al. Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies. PLoS Med. 2020;17(4):e1003100. doi: 10.1371\/journal.pmed.1003100","journal-title":"PLoS Med"},{"issue":"2","key":"key20231207093321_B22","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jhep.2019.03.033","article-title":"Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease","volume":"71","author":"Srivastava","year":"2019","unstructured":"22 Srivastava A, Gailer R, Tanwar S, Trembling P, Parkes J, Rodger A, et al. Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease. J Hepatol. 2019;71(2):371-8. doi: 10.1016\/j.jhep.2019.03.033","journal-title":"J Hepatol"},{"issue":"4","key":"key20231207093321_B23","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1136\/flgastro-2018-101155","article-title":"A multidisciplinary approach to the management of NAFLD is associated with improvement in markers of liver and cardio-metabolic health","volume":"10","author":"Moolla","year":"2019","unstructured":"23 Moolla A, Motohashi K, Marjot T, Shard A, Ainsworth M, Gray A, et al. A multidisciplinary approach to the management of NAFLD is associated with improvement in markers of liver and cardio-metabolic health. Frontline Gastroenterol. 2019;10(4):337-46. doi: 10.1136\/flgastro-2018-101155","journal-title":"Frontline Gastroenterol"},{"issue":"9403","key":"key20231207093321_B24","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0140-6736(03)15268-3","article-title":"Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies","volume":"363","author":"WHO Expert Consultation","year":"2004","unstructured":"24 WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363(9403):157-63. doi: 10.1016\/S0140-6736(03)15268-3.","journal-title":"Lancet"},{"issue":"3","key":"key20231207093321_B25","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/hep.24452","article-title":"Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis","volume":"54","author":"Hernaez","year":"2011","unstructured":"25 Hernaez R, Lazo M, Bonekamp S, Kamel I, Brancati FL, Guallar E, et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology. 2011;54(3):1082-90. doi: 10.1002\/hep.24452","journal-title":"Hepatology"},{"issue":"9","key":"key20231207093321_B26","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1111\/liv.12840","article-title":"Clinical value of liver ultrasound for the diagnosis of nonalcoholic fatty liver disease in overweight and obese patients","volume":"35","author":"Bril","year":"2015","unstructured":"26 Bril F, Ortiz-Lopez C, Lomonaco R, Orsak B, Freckleton M, Chintapalli K, et al. Clinical value of liver ultrasound for the diagnosis of nonalcoholic fatty liver disease in overweight and obese patients. Liver Int. 2015;35(9):2139-46. doi: 10.1111\/liv.12840","journal-title":"Liver Int"},{"issue":"5","key":"key20231207093321_B27","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1381\/096089204323093408","article-title":"The role of ultrasound in the diagnosis of hepatic steatosis in morbidly obese patients","volume":"14","author":"Mottin","year":"2004","unstructured":"27 Mottin CC, Moretto M, Padoin AV, Swarowsky AM, Toneto MG, Glock L, et al. The role of ultrasound in the diagnosis of hepatic steatosis in morbidly obese patients. Obes Surg. 2004;14(5):635-7. doi: 10.1381\/096089204323093408","journal-title":"Obes Surg"},{"issue":"7","key":"key20231207093321_B28","doi-asserted-by":"crossref","first-page":"3564","DOI":"10.1007\/s00330-019-06072-4","article-title":"Diagnostic value of MRI-PDFF for hepatic steatosis in patients with non-alcoholic fatty liver disease: a meta-analysis","volume":"29","author":"Gu","year":"2019","unstructured":"28 Gu J, Liu S, Du S, Zhang Q, Xiao J, Dong Q, et al. Diagnostic value of MRI-PDFF for hepatic steatosis in patients with non-alcoholic fatty liver disease: a meta-analysis. Eur Radiol. 2019;29(7):3564-73. doi: 10.1007\/s00330-019-06072-4","journal-title":"Eur Radiol"},{"issue":"2","key":"key20231207093321_B29","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/hep.29797","article-title":"Quantitative Assessment of Liver Fat by MRI-PDFF as an Endpoint in NASH Trials","volume":"68","author":"Caussy","year":"2018","unstructured":"29 Caussy C, Reeder SB, Sirlin CB, Loomba R. Noninvasive, Quantitative Assessment of Liver Fat by MRI-PDFF as an Endpoint in NASH Trials. Hepatology. 2018;68(2):763-72. doi: 10.1002\/hep.29797","journal-title":"Hepatology"},{"issue":"6","key":"key20231207093321_B30","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1053\/j.gastro.2019.01.042","article-title":"Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease","volume":"156","author":"Eddowes","year":"2019","unstructured":"30 Eddowes PJ, Sasso M, Allison M, Tsochatzis E, Anstee QM, Sheridan D, et al. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2019;156(6):1717-30. doi: 10.1053\/j.gastro.2019.01.042","journal-title":"Gastroenterology"},{"issue":"3","key":"key20231207093321_B31","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S2468-1253(20)30357-5","article-title":"Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis","volume":"6","author":"Petroff","year":"2021","unstructured":"31 Petroff D, Blank V, Newsome PN, Shalimar, Voican CS, Thiele M, et al. Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis. Lancet Gastroenterol Hepatol. 2021;6(3):185-98. doi: 10.1016\/S2468-1253(20)30357-5","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"key20231207093321_B32","doi-asserted-by":"crossref","first-page":"101547","DOI":"10.1016\/j.eclinm.2022.101547","article-title":"Accuracy of controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) for assessing steatosis and fibrosis in non-alcoholic fatty liver disease: A systematic review and meta-analysis","volume":"51","author":"Cao","year":"2022","unstructured":"32 Cao YT, Xiang LL, Qi F, Zhang YJ, Chen Y, Zhou XQ. Accuracy of controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) for assessing steatosis and fibrosis in non-alcoholic fatty liver disease: A systematic review and meta-analysis. EClinicalMedicine. 2022;51:101547. doi: 10.1016\/j.eclinm.2022.101547","journal-title":"EClinicalMedicine"},{"issue":"2","key":"key20231207093321_B33","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/liv.15127","article-title":"Accuracy of controlled attenuation parameter for assessing liver steatosis in individuals with morbid obesity before bariatric surgery","volume":"42","author":"Tavaglione","year":"2022","unstructured":"33 Tavaglione F, De Vincentis A, Bruni V, Gallo IF, Carotti S, Tuccinardi D, et al. Accuracy of controlled attenuation parameter for assessing liver steatosis in individuals with morbid obesity before bariatric surgery. Liver Int. 2022;42(2):374-83. doi: 10.1111\/liv.15127","journal-title":"Liver Int"},{"issue":"9","key":"key20231207093321_B34","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1111\/liv.12226","article-title":"Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD)","volume":"33","author":"Verma","year":"2013","unstructured":"34 Verma S, Jensen D, Hart J, Mohanty SR. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD). Liver Int. 2013;33(9):1398-405. doi: 10.1111\/liv.12226","journal-title":"Liver Int"},{"key":"key20231207093321_B35","doi-asserted-by":"crossref","first-page":"e000870","DOI":"10.1136\/bmjgast-2022-000870","article-title":"Updated upper limit of normal for serum alanine aminotransferase value in Vietnamese population","volume":"9","author":"Huong","year":"2022","unstructured":"35 Huong NT, Karimzadeh S, Thanh NT, Thuan TN, Sabbah GM, Ismaeil, K, et at. Updated upper limit of normal for serum alanine aminotransferase value in Vietnamese population. BMJ Open Gastroenterol. 2022;9:e000870. doi: 10.1136\/bmjgast-2022-000870.","journal-title":"BMJ Open Gastroenterol"},{"issue":"1","key":"key20231207093321_B36","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/ajg.2016.517","article-title":"ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries","volume":"112","author":"Kwo","year":"2017","unstructured":"36 Kwo PY, Cohen SM, Lim JK. ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries. Am J Gastroenterol. 2017;112(1):18-35. doi: 10.1038\/ajg.2016.517.","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"key20231207093321_B37","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1053\/jhep.2003.50229","article-title":"Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values","volume":"37","author":"Mofrad","year":"2003","unstructured":"37 Mofrad P, Contos MJ, Haque M, Sargeant C, Fisher RA, Luketic VA, et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology. 2003;37(6):1286-92. doi: 10.1053\/jhep.2003.50229","journal-title":"Hepatology"},{"issue":"4","key":"key20231207093321_B38","doi-asserted-by":"crossref","first-page":"427","DOI":"10.15403\/jgld-293","article-title":"Characterization of patients with biopsy-proven non-alcoholic fatty liver disease and normal aminotransferase levels","volume":"28","author":"Ulasoglu","year":"2019","unstructured":"38 Ulasoglu C, Enc FY, Kaya E, Yilmaz Y. Characterization of patients with biopsy-proven non-alcoholic fatty liver disease and normal aminotransferase levels. J Gastrointestin Liver Dis. 2019;28(4):427-31. doi: 10.15403\/jgld-293.","journal-title":"J Gastrointestin Liver Dis"},{"issue":"1","key":"key20231207093321_B39","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12876-020-1165-z","article-title":"Proportion of NAFLD patients with normal ALT value in overall NAFLD patients: a systematic review and meta-analysis","volume":"20","author":"Ma","year":"2020","unstructured":"39 Ma X, Liu S, Zhang J, Dong M, Wang Y, Wang M, et al. Proportion of NAFLD patients with normal ALT value in overall NAFLD patients: a systematic review and meta-analysis. BMC Gastroenterol. 2020;20(1):10. doi: 10.1186\/s12876-020-1165-z","journal-title":"BMC Gastroenterol"},{"issue":"6","key":"key20231207093321_B40","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1053\/j.gastro.2020.01.043","article-title":"Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis","volume":"158","author":"Taylor","year":"2020","unstructured":"40 Taylor RS, Taylor RJ, Bayliss S, Hagstrom H, Nasr P, Schattenberg JM, et al. Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Gastroenterology. 2020;158(6):1611-25.e12. doi: 10.1053\/j.gastro.2020.01.043","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"key20231207093321_B41","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/liv.14347","article-title":"Non-invasive tests for liver fibrosis in NAFLD: Creating pathways between primary healthcare and liver clinics","volume":"40","author":"Castera","year":"2020","unstructured":"41 Castera L. Non-invasive tests for liver fibrosis in NAFLD: Creating pathways between primary healthcare and liver clinics. Liver Int. 2020;40 Suppl 1:77-81. doi: 10.1111\/liv.14347","journal-title":"Liver Int"},{"issue":"5","key":"key20231207093321_B42","doi-asserted-by":"crossref","first-page":"466","DOI":"10.5152\/tjg.2021.20498","article-title":"Feasibility of fibroscan in assessment of hepatic steatosis and fibrosis in obese patients: Report from a general internal medicine clinic","volume":"32","author":"Avcu","year":"2021","unstructured":"42 Avcu A, Kaya E, Yilmaz Y. Feasibility of fibroscan in assessment of hepatic steatosis and fibrosis in obese patients: Report from a general internal medicine clinic. Turk J Gastroenterol. 2021;32(5):466-72. doi: 10.5152\/tjg.2021.20498.","journal-title":"Turk J Gastroenterol"},{"issue":"5","key":"key20231207093321_B43","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1007\/s11695-020-04996-1","article-title":"Performance of Noninvasive Liver Fibrosis Tests in Morbidly Obese Patients with Nonalcoholic Fatty Liver Disease","volume":"31","author":"Alqahtani","year":"2021","unstructured":"43 Alqahtani SA, Golabi P, Paik JM, Lam B, Moazez AH, Elariny HA, et al. Performance of Noninvasive Liver Fibrosis Tests in Morbidly Obese Patients with Nonalcoholic Fatty Liver Disease. Obes Surg. 2021;31(5):2002-10. doi:10.1007\/s11695-020-04996-1","journal-title":"Obes Surg"},{"issue":"10","key":"key20231207093321_B44","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1038\/s41366-021-00881-8","article-title":"Performance of non-invasive fibrosis scores in non-alcoholic fatty liver disease with and without morbid obesity","volume":"45","author":"Drolz","year":"2021","unstructured":"44 Drolz A, Wolter S, Wehmeyer MH, Piecha F, Horvatits T, Schulze Zur Wiesch J, et al. Performance of non-invasive fibrosis scores in non-alcoholic fatty liver disease with and without morbid obesity. Int J Obes (Lond). 2021;45(10):2197-204. doi: 10.1038\/s41366-021-00881-8","journal-title":"Int J Obes (Lond)"},{"issue":"4","key":"key20231207093321_B45","first-page":"486","volume":"14","author":"Kaya","year":"2020","unstructured":"45 Kaya E, Bakir A, Kani HT, Demirtas CO, Keklikkiran C, Yilmaz Y. Simple Noninvasive Scores Are Clinically Useful to Exclude, Not Predict, Advanced Fibrosis: A Study in Turkish Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease. 2020;14(4):486-91. doi: 10.5009\/gnl19173.","journal-title":"Simple Noninvasive Scores Are Clinically Useful to Exclude, Not Predict, Advanced Fibrosis: A Study in Turkish Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease"},{"issue":"10","key":"key20231207093321_B46","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1038\/s41366-021-00881-8","article-title":"Performance of non-invasive fibrosis scores in non-alcoholic fatty liver disease with and without morbid obesity","volume":"45","author":"Drolz","year":"2021","unstructured":"46 Drolz A, Wolter S, Wehmeyer MH, Piecha F, Horvatits T, Schulze Zur Wiesch J, et al. Performance of non-invasive fibrosis scores in non-alcoholic fatty liver disease with and without morbid obesity. Int J Obes (Lond). 2021;45(10):2197-204. doi: 10.1038\/s41366-021-00881-8.","journal-title":"Int J Obes (Lond)"},{"issue":"5","key":"key20231207093321_B47","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1007\/s11695-020-04996-1","article-title":"Performance of Noninvasive Liver Fibrosis Tests in Morbidly Obese Patients with Nonalcoholic Fatty Liver Disease","volume":"31","author":"Alqahtani","year":"2021","unstructured":"47 Alqahtani SA, Golabi P, Paik JM, Lam B, Moazez AH, Elariny HA, et al. Performance of Noninvasive Liver Fibrosis Tests in Morbidly Obese Patients with Nonalcoholic Fatty Liver Disease. Obes Surg. 2021;31(5):2002-10. doi: 10.1007\/s11695-020-04996-1.","journal-title":"Obes Surg"},{"issue":"5","key":"key20231207093321_B48","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1136\/gutjnl-2021-324243","article-title":"Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis","volume":"71","author":"M\u00f3zes","year":"2022","unstructured":"48 M\u00f3zes FE, Lee JA, Selvaraj EA, Jayaswal ANA, Trauner M, Boursier J, et al. Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. Gut. 2022;71(5):1006-19. doi:10.1136\/gutjnl-2021-324243","journal-title":"Gut"},{"issue":"9","key":"key20231207093321_B49","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/hepr.12647","article-title":"Comparison of FIB-4 index, NAFLD fibrosis score and BARD score for prediction of advanced fibrosis in adult patients with non-alcoholic fatty liver disease: A meta-analysis study","volume":"46","author":"Sun","year":"2016","unstructured":"49 Sun W, Cui H, Li N, Wei Y, Lai S, Yang Y, et al. Comparison of FIB-4 index, NAFLD fibrosis score and BARD score for prediction of advanced fibrosis in adult patients with non-alcoholic fatty liver disease: A meta-analysis study. Hepatol Res. 2016;46(9):862-70. doi: 10.1111\/hepr.12647","journal-title":"Hepatol Res"},{"issue":"3","key":"key20231207093321_B50","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/apt.15830","article-title":"Clinical assessment for high-risk patients with non-alcoholic fatty liver disease in primary care and diabetology practices","volume":"52","author":"Younossi","year":"2020","unstructured":"50 Younossi ZM, Corey KE, Alkhouri N, Noureddin M, Jacobson I, Lam B, et al. Clinical assessment for high-risk patients with non-alcoholic fatty liver disease in primary care and diabetology practices. Aliment Pharmacol Ther.2020;52(3):513-26. doi: 10.1111\/apt.15830.","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"key20231207093321_B51","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.jhep.2021.04.044","article-title":"Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis","volume":"75","author":"Selvaraj","year":"2021","unstructured":"51 Selvaraj EA, Mozes FE, Jayaswal ANA, Zafarmand MH, Vali Y, Lee JA, et al. Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis. J Hepatol. 2021;75(4):770-85. doi: 10.1016\/j.jhep.2021.04.044","journal-title":"J Hepatol"},{"issue":"5","key":"key20231207093321_B52","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1002\/hep.29302","article-title":"Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: A meta-analysis","volume":"66","author":"Xiao","year":"2017","unstructured":"52 Xiao G, Zhu S, Xiao X, Yan L, Yang J, Wu G. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: A meta-analysis. Hepatology. 2017;66(5):1486-501. doi: 10.1002\/hep.29302","journal-title":"Hepatology"},{"issue":"11","key":"key20231207093321_B53","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1136\/gutjnl-2018-317334","article-title":"Unified interpretation of liver stiffness measurement by M and XL probes in non-alcoholic fatty liver disease","volume":"68","author":"Wong","year":"2019","unstructured":"53 Wong VW, Irles M, Wong GL, Shili S, Chan AW, Merrouche W, et al. Unified interpretation of liver stiffness measurement by M and XL probes in non-alcoholic fatty liver disease. Gut. 2019;68(11):2057-64. doi: 10.1136\/gutjnl-2018-317334","journal-title":"Gut"},{"issue":"3","key":"key20231207093321_B54","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","article-title":"Electronic address: easloffice@easloffice.eu; Clinical Practice Guideline Panel; Chair; EASL Governing Board representative; Panel members. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update","volume":"75","author":"European Association for the Study of the Liver","year":"2021","unstructured":"54 European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; Clinical Practice Guideline Panel; Chair; EASL Governing Board representative; Panel members. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update. J Hepatol. 2021;75(3):659-89. doi: 10.1016\/j.jhep.2021.05.025","journal-title":"J Hepatol"},{"issue":"4","key":"key20231207093321_B55","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/hep.27844","article-title":"The severity of steatosis influences liver stiffness measurement in patients with nonalcoholic fatty liver disease","volume":"62","author":"Petta","year":"2015","unstructured":"55 Petta S, Maida M, Macaluso FS, Di Marco V, Camma C, Cabibi D, et al. The severity of steatosis influences liver stiffness measurement in patients with nonalcoholic fatty liver disease. Hepatology. 2015;62(4):1101-10. doi: 10.1002\/hep.27844","journal-title":"Hepatology"},{"issue":"12","key":"key20231207093321_B56","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1016\/j.cgh.2017.10.037","article-title":"Association Between Obesity and Discordance in Fibrosis Stage Determination by Magnetic Resonance vs Transient Elastography in Patients With Nonalcoholic Liver Disease","volume":"16","author":"Caussy","year":"2018","unstructured":"56 Caussy C, Chen J, Alquiraish MH, Cepin S, Nguyen P, Hernandez C, et al. Association Between Obesity and Discordance in Fibrosis Stage Determination by Magnetic Resonance vs Transient Elastography in Patients With Nonalcoholic Liver Disease. Clin Gastroenterol Hepatol. 2018;16(12):1974-82.e7. doi: 10.1016\/j.cgh.2017.10.037","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"key20231207093321_B57","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.cgh.2018.05.059","article-title":"Magnetic Resonance vs Transient Elastography Analysis of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Pooled Analysis of Individual Participants","volume":"17","author":"Hsu","year":"2019","unstructured":"57 Hsu C, Caussy C, Imajo K, Chen J, Singh S, Kaulback K, et al. Magnetic Resonance vs Transient Elastography Analysis of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Pooled Analysis of Individual Participants. Clin Gastroenterol Hepatol. 2019;17(4):630-7.e8. doi: 10.1016\/j.cgh.2018.05.059","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"key20231207093321_B58","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1007\/s11695-017-2606-9","article-title":"Utility of the ELF Test for Detecting Steatohepatitis in Morbid Obese Patients with Suspicion of Nonalcoholic Fatty Liver Disease","volume":"27","author":"Lopez","year":"2017","unstructured":"58 Lopez IC, Aroca FG, Bernal MDF, Mompean JAL, Bernal AB, Martinez AMH, et al. Utility of the ELF Test for Detecting Steatohepatitis in Morbid Obese Patients with Suspicion of Nonalcoholic Fatty Liver Disease. Obes Surg. 2017;27(9):2347-53. doi: 10.1007\/s11695-017-2606-9","journal-title":"Obes Surg"},{"issue":"2","key":"key20231207093321_B59","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jhep.2020.03.036","article-title":"Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis","volume":"73","author":"Vali","year":"2020","unstructured":"59 Vali Y, Lee J, Boursier J, Spijker R, Loffler J, Verheij J, et al. Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis. J Hepatol. 2020;73(2):252-62. doi: 10.1016\/j.jhep.2020.03.036","journal-title":"J Hepatol"},{"issue":"5","key":"key20231207093321_B60","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/hep.29085","article-title":"Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis","volume":"65","author":"Dulai","year":"2017","unstructured":"60 Dulai PS, Singh S, Patel J, Soni M, Prokop LJ, Younossi Z, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. Hepatology. 2017;65(5):1557-65. doi: 10.1002\/hep.29085","journal-title":"Hepatology"},{"issue":"4","key":"key20231207093321_B61","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.cgh.2014.04.014","article-title":"Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies","volume":"13","author":"Singh","year":"2015","unstructured":"61 Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2015;13(4):643-54.e1-9; quiz e39-40. doi: 10.1016\/j.cgh.2014.04.014","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"key20231207093321_B62","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1097\/MEG.0000000000001573","article-title":"The diagnostic utility of fibrosis-4 or nonalcoholic fatty liver disease fibrosis score combined with liver stiffness measurement by fibroscan in assessment of advanced liver fibrosis: a biopsy-proven nonalcoholic fatty liver disease study","volume":"32","author":"Fuad","year":"2020","unstructured":"62 Fuad J, Eda K, Fatih E, Yusuf Y. The diagnostic utility of fibrosis-4 or nonalcoholic fatty liver disease fibrosis score combined with liver stiffness measurement by fibroscan in assessment of advanced liver fibrosis: a biopsy-proven nonalcoholic fatty liver disease study. Eur J Gastroenterol Hepatol.2020;32(5):642-9. doi: 10.1097\/MEG.0000000000001573.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"6","key":"key20231207093321_B63","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.jhep.2017.07.027","article-title":"Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD","volume":"67","author":"Hagstrom","year":"2017","unstructured":"63 Hagstrom H, Nasr P, Ekstedt M, Hammar U, Stal P, Hultcrantz R, et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J Hepatol. 2017;67(6):1265-73. doi: 10.1016\/j.jhep.2017.07.027","journal-title":"J Hepatol"},{"issue":"9","key":"key20231207093321_B64","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1016\/j.cgh.2018.12.031","article-title":"Diagnostic Accuracy of Noninvasive Fibrosis Models to Detect Change in Fibrosis Stage","volume":"17","author":"Siddiqui","year":"2019","unstructured":"64 Siddiqui MS, Yamada G, Vuppalanchi R, Van Natta M, Loomba R, Guy C, et al. Diagnostic Accuracy of Noninvasive Fibrosis Models to Detect Change in Fibrosis Stage. Clin Gastroenterol Hepatol. 2019;17(9):1877-85.e5. doi: 10.1016\/j.cgh.2018.12.031","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"key20231207093321_B65","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1111\/liv.13974","article-title":"Relationship between three commonly used non-invasive fibrosis biomarkers and improvement in fibrosis stage in patients with non-alcoholic steatohepatitis","volume":"39","author":"Chalasani","year":"2019","unstructured":"65 Chalasani N, Abdelmalek MF, Loomba R, Kowdley KV, McCullough AJ, Dasarathy S, et al. Relationship between three commonly used non-invasive fibrosis biomarkers and improvement in fibrosis stage in patients with non-alcoholic steatohepatitis. Liver Int. 2019;39(5):924-32. doi: 10.1111\/liv.13974","journal-title":"Liver Int"},{"issue":"6","key":"key20231207093321_B66","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1002\/hep.30664","article-title":"The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials","volume":"70","author":"Sanyal","year":"2019","unstructured":"66 Sanyal AJ, Harrison SA, Ratziu V, Abdelmalek MF, Diehl AM, Caldwell S, et al. The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials. Hepatology. 2019;70(6):1913-27. doi: 10.1002\/hep.30664","journal-title":"Hepatology"},{"issue":"4","key":"key20231207093321_B67","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.cgh.2020.06.045","article-title":"Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver Disease","volume":"19","author":"Petta","year":"2021","unstructured":"67 Petta S, Sebastiani G, Vigano M, Ampuero J, Wai-Sun Wong V, Boursier J, et al. Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver Disease. Clin Gastroenterol Hepatol. 2021;19(4):806-15.e5. doi: 10.1016\/j.cgh.2020.06.045","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"key20231207093321_B68","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/hepr.12039","article-title":"Transient elastography for monitoring the fibrosis of non-alcoholic fatty liver disease for 4 years","volume":"43","author":"Suzuki","year":"2013","unstructured":"68 Suzuki K, Yoneda M, Imajo K, Kirikoshi H, Nakajima A, Maeda S, et al. Transient elastography for monitoring the fibrosis of non-alcoholic fatty liver disease for 4 years. Hepatol Res. 2013;43(9):979-83. doi: 10.1111\/hepr.12039","journal-title":"Hepatol Res"},{"issue":"3","key":"key20231207093321_B69","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1002\/hep.30974","article-title":"Clinical utility of an increase in magnetic resonance elastography in predicting fibrosis progression in nonalcoholic fatty liver disease","volume":"71","author":"Ajmera","year":"2020","unstructured":"69 Ajmera VH, Liu A, Singh S, Yachoa G, Ramey M, Bhargava M, et al. Clinical utility of an increase in magnetic resonance elastography in predicting fibrosis progression in nonalcoholic fatty liver disease. Hepatology. 2020;71(3):849-60. doi: 10.1002\/hep.30974","journal-title":"Hepatology"},{"issue":"1","key":"key20231207093321_B70","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","unstructured":"70 Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328-57. doi: 10.1002\/hep.29367","journal-title":"Hepatology"},{"issue":"5","key":"key20231207093321_B71","doi-asserted-by":"crossref","first-page":"281","DOI":"10.6061\/clinics\/2016(05)07","article-title":"Nonalcoholic steatohepatitis and hepatocellular carcinoma: Brazilian survey","volume":"71","author":"Cotrim","year":"2016","unstructured":"71 Cotrim HP, Oliveira CP, Coelho HS, Alvares-da-Silva MR, Nabuco L, Parise ER, et al. Nonalcoholic steatohepatitis and hepatocellular carcinoma: Brazilian survey. Clinics (Sao Paulo). 2016;71(5):281-4. doi: 10.6061\/clinics\/2016(05)07","journal-title":"Clinics (Sao Paulo)"},{"issue":"7","key":"key20231207093321_B72","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1111\/apt.14937","article-title":"Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases","volume":"48","author":"Stine","year":"2018","unstructured":"72 Stine JG, Wentworth BJ, Zimmet A, Rinella ME, Loomba R, Caldwell SH, et al. Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases. Aliment Pharmacol Ther. 2018;48(7):696-703. doi: 10.1111\/apt.14937","journal-title":"Aliment Pharmacol Ther"},{"key":"key20231207093321_B73","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1146\/annurev-med-090514-013832","article-title":"Liver Cancer: Connections with Obesity, Fatty Liver, and Cirrhosis","volume":"67","author":"Marengo","year":"2016","unstructured":"73 Marengo A, Rosso C, Bugianesi E. Liver Cancer: Connections with Obesity, Fatty Liver, and Cirrhosis. Annu Rev Med. 2016;67:103-17. doi: 10.1146\/annurev-med-090514-013832","journal-title":"Annu Rev Med"},{"issue":"6","key":"key20231207093321_B74","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1053\/j.gastro.2018.08.024","article-title":"Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease","volume":"155","author":"Kanwal","year":"2018","unstructured":"74 Kanwal F, Kramer JR, Mapakshi S, Natarajan Y, Chayanupatkul M, Richardson PA, et al. Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease. Gastroenterology. 2018;155(6):1828-37.e2. doi: 10.1053\/j.gastro.2018.08.024","journal-title":"Gastroenterology"},{"issue":"2","key":"key20231207093321_B75","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.atherosclerosis.2013.07.052","article-title":"A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care?","volume":"230","author":"Oni","year":"2013","unstructured":"75 Oni ET, Agatston AS, Blaha MJ, Fialkow J, Cury R, Sposito A, et al. A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care? Atherosclerosis. 2013;230(2):258-67. doi: 10.1016\/j.atherosclerosis.2013.07.052","journal-title":"Atherosclerosis"},{"key":"key20231207093321_B76","doi-asserted-by":"crossref","first-page":"33386","DOI":"10.1038\/srep33386","article-title":"Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: A systematic review and meta-analysis","volume":"6","author":"Wu","year":"2016","unstructured":"76 Wu S, Wu F, Ding Y, Hou J, Bi J, Zhang Z. Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: A systematic review and meta-analysis. Sci Rep. 2016;6:33386. doi: 10.1038\/srep33386","journal-title":"Sci Rep"},{"issue":"6","key":"key20231207093321_B77","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1161\/ATV.0000000000000153","article-title":"Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association","volume":"42","author":"Duell","year":"2022","unstructured":"77 Duell PB, Welty FK, Miller M, Chait A, Hammond G, Ahmad Z, et al. Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol. 2022;42(6):e168-e85. doi: 10.1161\/ATV.0000000000000153","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"11","key":"key20231207093321_B78","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S2468-1253(21)00308-3","article-title":"Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis","volume":"6","author":"Mantovani","year":"2021","unstructured":"78 Mantovani A, Csermely A, Petracca G, Beatrice G, Corey KE, Simon TG, et al. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2021;6(11):903-13. doi: 10.1016\/S2468-1253(21)00308-3","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"14","key":"key20231207093321_B79","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1056\/NEJMra0912063","article-title":"Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease","volume":"363","author":"Targher","year":"2010","unstructured":"79 Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med. 2010;363(14):1341-50. doi: 10.1056\/NEJMra0912063","journal-title":"N Engl J Med"},{"issue":"6","key":"key20231207093321_B80","first-page":"440","article-title":"Association between nonalcoholic fatty liver disease and colorectal adenoma: a systemic review and meta-analysis","volume":"5","author":"Shen","year":"2014","unstructured":"80 Shen H, Lipka S, Kumar A, Mustacchia P. Association between nonalcoholic fatty liver disease and colorectal adenoma: a systemic review and meta-analysis. J Gastrointest Oncol. 2014;5(6):440-6. doi: 10.3978\/j.issn.2078-6891.2014.061","journal-title":"J Gastrointest Oncol"},{"issue":"2","key":"key20231207093321_B81","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/apt.13866","article-title":"Non-alcoholic fatty liver diseases and risk of colorectal neoplasia","volume":"45","author":"Ahn","year":"2017","unstructured":"81 Ahn JS, Sinn DH, Min YW, Hong SN, Kim HS, Jung SH, et al. Non-alcoholic fatty liver diseases and risk of colorectal neoplasia. Aliment Pharmacol Ther. 2017;45(2):345-53. doi: 10.1111\/apt.13866","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"key20231207093321_B82","doi-asserted-by":"crossref","first-page":"603","DOI":"10.2337\/diabetes.54.3.603","article-title":"Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes","volume":"54","author":"Petersen","year":"2005","unstructured":"82 Petersen KF, Dufour S, Befroy D, Lehrke M, Hendler RE, Shulman GI. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes. 2005;54(3):603-8. doi: 10.2337\/diabetes.54.3.603","journal-title":"Diabetes"},{"issue":"25 Pt B","key":"key20231207093321_B83","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1016\/j.jacc.2013.11.004","article-title":"2013 AHA\/ACC\/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and The Obesity Society","volume":"63","author":"Jensen","year":"2014","unstructured":"83 Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA, et al. 2013 AHA\/ACC\/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol 2014;63(25 Pt B):2985-3023. doi: 10.1016\/j.jacc.2013.11.004.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"key20231207093321_B84","first-page":"97","article-title":"Sustainability of diet-based moderate calorie restriction among obese patients with metabolic-associated fatty liver disease","volume":"2","author":"Guveli","year":"2021","unstructured":"84 Guveli H, Ozlu T, Tasar BE, Kenger EB, Kaya E. Sustainability of diet-based moderate calorie restriction among obese patients with metabolic-associated fatty liver disease. Hepato Forum. 2021;2(3):97-101. doi: 10.14744\/hf.2021.2021.0014","journal-title":"Hepato Forum"},{"key":"key20231207093321_B85","doi-asserted-by":"crossref","first-page":"154455","DOI":"10.1016\/j.metabol.2020.154455","article-title":"The effect of the magnitude of weight loss on non-alcoholic fatty liver disease: A systematic review and meta-analysis","volume":"115","author":"Koutoukidis","year":"2021","unstructured":"85 Koutoukidis DA, Koshiaris C, Henry JA, Noreik M, Morris E, Manoharan I, et al. The effect of the magnitude of weight loss on non-alcoholic fatty liver disease: A systematic review and meta-analysis. Metabolism. 2021;115:154455. doi: 10.1016\/j.metabol.2020.154455","journal-title":"Metabolism"},{"issue":"2","key":"key20231207093321_B86","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis","volume":"149","author":"Vilar-Gomez","year":"2015","unstructured":"86 Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L, et al. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology. 2015;149(2):367-78.e5; quiz e14-5. doi: 10.1053\/j.gastro.2015.04.005","journal-title":"Gastroenterology"},{"issue":"1","key":"key20231207093321_B87","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/hep.23276","article-title":"Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis","volume":"51","author":"Promrat","year":"2010","unstructured":"87 Promrat K, Kleiner DE, Niemeier HM, Jackvony E, Kearns M, Wands JR, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology. 2010;51(1):121-9. doi: 10.1002\/hep.23276","journal-title":"Hepatology"},{"issue":"10","key":"key20231207093321_B88","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.2337\/dc10-0856","article-title":"Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes","volume":"33","author":"Lazo","year":"2010","unstructured":"88 Lazo M, Solga SF, Horska A, Bonekamp S, Diehl AM, Brancati FL, et al. Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes. Diabetes Care. 2010;33(10):2156-63. doi: 10.2337\/dc10-0856","journal-title":"Diabetes Care"},{"issue":"11","key":"key20231207093321_B89","doi-asserted-by":"crossref","first-page":"3786","DOI":"10.2337\/dc13-0102","article-title":"Long-lasting improvements in liver fat and metabolism despite body weight regain after dietary weight loss","volume":"36","author":"Haufe","year":"2013","unstructured":"89 Haufe S, Haas V, Utz W, Birkenfeld AL, Jeran S, Bohnke J, et al. Long-lasting improvements in liver fat and metabolism despite body weight regain after dietary weight loss. Diabetes Care 2013;36(11):3786-92. doi: 10.2337\/dc13-0102.","journal-title":"Diabetes Care"},{"key":"key20231207093321_B90","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.metabol.2016.12.006","article-title":"Effects of lifestyle interventions on clinical characteristics of patients with non-alcoholic fatty liver disease: A meta-analysis","volume":"68","author":"Katsagoni","year":"2017","unstructured":"90 Katsagoni CN, Georgoulis M, Papatheodoridis GV, Panagiotakos DB, Kontogianni MD. Effects of lifestyle interventions on clinical characteristics of patients with non-alcoholic fatty liver disease: A meta-analysis. Metabolism. 2017;68:119-32. doi: 10.1016\/j.metabol.2016.12.006","journal-title":"Metabolism"},{"issue":"1","key":"key20231207093321_B91","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/1753-0407.13086","article-title":"Effect of exercise on hepatic steatosis: Are benefits seen without dietary intervention? A systematic review and meta-analysis","volume":"13","author":"Baker","year":"2021","unstructured":"91 Baker CJ, Martinez-Huenchullan SF, D\u2019Souza M, Xu Y, Li M, Bi Y, et al. Effect of exercise on hepatic steatosis: Are benefits seen without dietary intervention? A systematic review and meta-analysis. J Diabetes. 2021;13(1):63-77. doi: 10.1111\/1753-0407.13086","journal-title":"J Diabetes"},{"issue":"6","key":"key20231207093321_B92","first-page":"CD013156","article-title":"Lifestyle modifications for nonalcohol-related fatty liver disease: a network meta-analysis","volume":"6","author":"Buzzetti","year":"2021","unstructured":"92 Buzzetti E, Linden A, Best LM, Madden AM, Roberts D, Chase TJG, et al. Lifestyle modifications for nonalcohol-related fatty liver disease: a network meta-analysis. Cochrane Database Syst Rev. 2021;6(6):CD013156. doi: 10.1002\/14651858.CD013156.pub2","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"key20231207093321_B93","doi-asserted-by":"crossref","DOI":"10.3390\/nu9080870","article-title":"Effect of Mediterranean Diet and Antioxidant Formulation in Non-Alcoholic Fatty Liver Disease: A Randomized Study","volume":"9","author":"Abenavoli","year":"2017","unstructured":"93 Abenavoli L, Greco M, Milic N, Accattato F, Foti D, Gulletta E, et al. Effect of Mediterranean Diet and Antioxidant Formulation in Non-Alcoholic Fatty Liver Disease: A Randomized Study. Nutrients. 2017;9(8). doi: 10.3390\/nu9080870","journal-title":"Nutrients"},{"issue":"2","key":"key20231207093321_B94","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jhep.2019.04.013","article-title":"The beneficial effects of Mediterranean diet over low-fat diet may be mediated by decreasing hepatic fat content","volume":"71","author":"Gepner","year":"2019","unstructured":"94 Gepner Y, Shelef I, Komy O, Cohen N, Schwarzfuchs D, Bril N, et al. The beneficial effects of Mediterranean diet over low-fat diet may be mediated by decreasing hepatic fat content. J Hepatol. 2019;71(2):379-88. doi: 10.1016\/j.jhep.2019.04.013","journal-title":"J Hepatol"},{"issue":"4","key":"key20231207093321_B95","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/s41430-020-00778-1","article-title":"Effects of dietary macronutrients on liver fat content in adults: a systematic review and meta-analysis of randomized controlled trials","volume":"75","author":"Winters-van Eekelen","year":"2021","unstructured":"95 Winters-van Eekelen E, Verkouter I, Peters HPF, Alssema M, de Roos BG, Schrauwen-Hinderling VB, et al. Effects of dietary macronutrients on liver fat content in adults: a systematic review and meta-analysis of randomized controlled trials. Eur J Clin Nutr. 2021;75(4):588-601. doi: 10.1038\/s41430-020-00778-1","journal-title":"Eur J Clin Nutr"},{"key":"key20231207093321_B96","doi-asserted-by":"crossref","first-page":"593735","DOI":"10.3389\/fnut.2020.593735","article-title":"Association Between Dietary Fiber Intake and Non-alcoholic Fatty Liver Disease in Adults","volume":"7","author":"Zhao","year":"2020","unstructured":"96 Zhao H, Yang A, Mao L, Quan Y, Cui J, Sun Y. Association Between Dietary Fiber Intake and Non-alcoholic Fatty Liver Disease in Adults. Front Nutr. 2020;7:593735. doi: 10.3389\/fnut.2020.593735","journal-title":"Front Nutr"},{"issue":"6","key":"key20231207093321_B97","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1002\/hep.23535","article-title":"Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease","volume":"51","author":"Abdelmalek","year":"2010","unstructured":"97 Abdelmalek MF, Suzuki A, Guy C, Unalp-Arida A, Colvin R, Johnson RJ, et al. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology. 2010;51(6):1961-71. doi: 10.1002\/hep.23535","journal-title":"Hepatology"},{"issue":"2","key":"key20231207093321_B98","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3945\/ajcn.111.022533","article-title":"Sucrose-sweetened beverages increase fat storage in the liver, muscle, and visceral fat depot: a 6-mo randomized intervention study","volume":"95","author":"Maersk","year":"2012","unstructured":"98 Maersk M, Belza A, Stodkilde-Jorgensen H, Ringgaard S, Chabanova E, Thomsen H, et al. Sucrose-sweetened beverages increase fat storage in the liver, muscle, and visceral fat depot: a 6-mo randomized intervention study. Am J Clin Nutr. 2012;95(2):283-9. doi: 10.3945\/ajcn.111.022533","journal-title":"Am J Clin Nutr"},{"issue":"2","key":"key20231207093321_B99","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.jhep.2015.03.032","article-title":"Sugar-sweetened beverage, diet soda, and fatty liver disease in the Framingham Heart Study cohorts","volume":"63","author":"Ma","year":"2015","unstructured":"99 Ma J, Fox CS, Jacques PF, Speliotes EK, Hoffmann U, Smith CE, et al. Sugar-sweetened beverage, diet soda, and fatty liver disease in the Framingham Heart Study cohorts. J Hepatol. 2015;63(2):462-9. doi: 10.1016\/j.jhep.2015.03.032","journal-title":"J Hepatol"},{"issue":"4","key":"key20231207093321_B100","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/ejcn.2014.8","article-title":"Effect of fructose on markers of non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of controlled feeding trials","volume":"68","author":"Chiu","year":"2014","unstructured":"100 Chiu S, Sievenpiper JL, de Souza RJ, Cozma AI, Mirrahimi A, Carleton AJ, et al. Effect of fructose on markers of non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of controlled feeding trials. Eur J Clin Nutr. 2014;68(4):416-23. doi: 10.1038\/ejcn.2014.8","journal-title":"Eur J Clin Nutr"},{"issue":"2","key":"key20231207093321_B101","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1093\/ajcn\/nqaa332","article-title":"Effects of fructose restriction on liver steatosis (FRUITLESS); a double-blind randomized controlled trial","volume":"113","author":"Simons","year":"2021","unstructured":"101 Simons N, Veeraiah P, Simons P, Schaper NC, Kooi ME, Schrauwen-Hinderling VB, et al. Effects of fructose restriction on liver steatosis (FRUITLESS); a double-blind randomized controlled trial. Am J Clin Nutr. 2021;113(2):391-400. doi: 10.1093\/ajcn\/nqaa332","journal-title":"Am J Clin Nutr"},{"issue":"1","key":"key20231207093321_B102","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/ije\/dyab174","article-title":"Ultra-processed food consumption and the risk of non-alcoholic fatty liver disease in the Tianjin Chronic Low-grade Systemic Inflammation and Health Cohort Study","volume":"51","author":"Zhang","year":"2022","unstructured":"102 Zhang S, Gan S, Zhang Q, Liu L, Meng G, Yao Z, et al. Ultra-processed food consumption and the risk of non-alcoholic fatty liver disease in the Tianjin Chronic Low-grade Systemic Inflammation and Health Cohort Study. Int J Epidemiol. 2022;51(1):237-49. doi:10.1093\/ije\/dyab174","journal-title":"Int J Epidemiol"},{"issue":"4","key":"key20231207093321_B103","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1056\/NEJMra1816604","article-title":"Coffee, Caffeine, and Health","volume":"383","author":"van Dam","year":"2020","unstructured":"103 van Dam RM, Hu FB, Willett WC. Coffee, Caffeine, and Health. N Engl J Med. 2020;383(4):369-78. doi:10.1056\/NEJMra1816604","journal-title":"N Engl J Med"},{"issue":"5","key":"key20231207093321_B104","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/apt.13523","article-title":"Systematic review with meta-analysis: coffee consumption and the risk of cirrhosis","volume":"43","author":"Kennedy","year":"2016","unstructured":"104 Kennedy OJ, Roderick P, Buchanan R, Fallowfield JA, Hayes PC, Parkes J. Systematic review with meta-analysis: coffee consumption and the risk of cirrhosis. Aliment Pharmacol Ther. 2016;43(5):562-74. doi:10.1111\/apt.13523","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"key20231207093321_B105","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/liv.12304","article-title":"Impact of coffee on liver diseases: a systematic review","volume":"34","author":"Saab","year":"2014","unstructured":"105 Saab S, Mallam D, Cox GA 2nd, Tong MJ. Impact of coffee on liver diseases: a systematic review. Liver Int. 2014;34(4):495-504. doi: 10.1111\/liv.12304","journal-title":"Liver Int"},{"issue":"6","key":"key20231207093321_B106","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1016\/j.clnu.2018.11.030","article-title":"A systematic review and a dose-response meta-analysis of coffee dose and nonalcoholic fatty liver disease","volume":"38","author":"Chen","year":"2019","unstructured":"106 Chen YP, Lu FB, Hu YB, Xu LM, Zheng MH, Hu ED. A systematic review and a dose-response meta-analysis of coffee dose and nonalcoholic fatty liver disease. Clin Nutr. 2019;38(6):2552-7. doi: 10.1016\/j.clnu.2018.11.030","journal-title":"Clin Nutr"},{"issue":"2","key":"key20231207093321_B107","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1097\/MEG.0000000000000776","article-title":"Coffee consumption and risk of nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"29","author":"Wijarnpreecha","year":"2017","unstructured":"107 Wijarnpreecha K, Thongprayoon C, Ungprasert P. Coffee consumption and risk of nonalcoholic fatty liver disease: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2017;29(2):e8-e12. doi: 10.1097\/MEG.0000000000000776","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"key20231207093321_B108","doi-asserted-by":"crossref","first-page":"100254","DOI":"10.1016\/j.aohep.2020.08.071","article-title":"The effect of coffee consumption on the non-alcoholic fatty liver disease and liver fibrosis: A meta-analysis of 11 epidemiological studies","volume":"20","author":"Hayat","year":"2021","unstructured":"108 Hayat U, Siddiqui AA, Okut H, Afroz S, Tasleem S, Haris A. The effect of coffee consumption on the non-alcoholic fatty liver disease and liver fibrosis: A meta-analysis of 11 epidemiological studies. Ann Hepatol. 2021;20:100254. doi: 10.1016\/j.aohep.2020.08.071","journal-title":"Ann Hepatol"},{"issue":"2","key":"key20231207093321_B109","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.jhep.2012.03.024","article-title":"Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD)","volume":"57","author":"Dunn","year":"2012","unstructured":"109 Dunn W, Sanyal AJ, Brunt EM, Unalp-Arida A, Donohue M, McCullough AJ, et al. Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD). J Hepatol. 2012;57(2):384-91. doi: 10.1016\/j.jhep.2012.03.024","journal-title":"J Hepatol"},{"issue":"1","key":"key20231207093321_B110","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/liv.12230","article-title":"Effect of lifetime alcohol consumption on the histological severity of non-alcoholic fatty liver disease","volume":"34","author":"Kwon","year":"2014","unstructured":"110 Kwon HK, Greenson JK, Conjeevaram HS. Effect of lifetime alcohol consumption on the histological severity of non-alcoholic fatty liver disease. Liver Int. 2014;34(1):129-35. doi: 10.1111\/liv.12230","journal-title":"Liver Int"},{"issue":"3","key":"key20231207093321_B111","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1080\/00365520802555991","article-title":"Alcohol consumption is associated with progression of hepatic fibrosis in non-alcoholic fatty liver disease","volume":"44","author":"Ekstedt","year":"2009","unstructured":"111 Ekstedt M, Franzen LE, Holmqvist M, Bendtsen P, Mathiesen UL, Bodemar G, et al. Alcohol consumption is associated with progression of hepatic fibrosis in non-alcoholic fatty liver disease. Scand J Gastroenterol. 2009;44(3):366-74. doi: 10.1080\/00365520802555991","journal-title":"Scand J Gastroenterol"},{"issue":"1","key":"key20231207093321_B112","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/hep.30170","article-title":"Nonheavy Drinking and Worsening of Noninvasive Fibrosis Markers in Nonalcoholic Fatty Liver Disease: A Cohort Study","volume":"69","author":"Chang","year":"2019","unstructured":"112 Chang Y, Cho YK, Kim Y, Sung E, Ahn J, Jung HS, et al. Nonheavy Drinking and Worsening of Noninvasive Fibrosis Markers in Nonalcoholic Fatty Liver Disease: A Cohort Study. Hepatology. 2019;69(1):64-75. doi: 10.1002\/hep.30170","journal-title":"Hepatology"},{"key":"key20231207093321_B113","doi-asserted-by":"crossref","first-page":"c1240","DOI":"10.1136\/bmj.c1240","article-title":"Effect of body mass index and alcohol consumption on liver disease: analysis of data from two prospective cohort studies","volume":"340","author":"Hart","year":"2010","unstructured":"113 Hart CL, Morrison DS, Batty GD, Mitchell RJ, Davey Smith G. Effect of body mass index and alcohol consumption on liver disease: analysis of data from two prospective cohort studies. BMJ. 2010;340:c1240. doi: 10.1136\/bmj.c1240","journal-title":"BMJ"},{"issue":"1","key":"key20231207093321_B114","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3892\/br.2012.18","article-title":"Metformin in non-alcoholic fatty liver disease: A systematic review and meta-analysis","volume":"1","author":"Li","year":"2013","unstructured":"114 Li Y, Liu L, Wang B, Wang J, Chen D. Metformin in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Biomed Rep. 2013;1(1):57-64. doi: 10.3892\/br.2012.18","journal-title":"Biomed Rep"},{"issue":"43","key":"key20231207093321_B115","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000031437","article-title":"Effect of metformin on nonalcoholic fatty liver based on meta-analysis and network pharmacology","volume":"101","author":"Huang","year":"2022","unstructured":"115 Huang Y, Wang X, Yan C, Li C, Zhang L, Zhang L, et al. Effect of metformin on nonalcoholic fatty liver based on meta-analysis and network pharmacology. Medicine (Baltimore). 2022;101(43):e31437. doi: 10.1097\/MD.0000000000031437.","journal-title":"Medicine (Baltimore)"},{"key":"key20231207093321_B116","doi-asserted-by":"crossref","first-page":"104799","DOI":"10.1016\/j.phrs.2020.104799","article-title":"The effects of metformin administration on liver enzymes and body composition in non-diabetic patients with non-alcoholic fatty liver disease and\/or non-alcoholic steatohepatitis: An up-to date systematic review and meta-analysis of randomized controlled trials","volume":"159","author":"Jalali","year":"2020","unstructured":"116 Jalali M, Rahimlou M, Mahmoodi M, Moosavian SP, Symonds ME, Jalali R, et al. The effects of metformin administration on liver enzymes and body composition in non-diabetic patients with non-alcoholic fatty liver disease and\/or non-alcoholic steatohepatitis: An up-to date systematic review and meta-analysis of randomized controlled trials. Pharmacol Res. 2020;159:104799. doi: 10.1016\/j.phrs.2020.104799.","journal-title":"Pharmacol Res"},{"issue":"1","key":"key20231207093321_B117","first-page":"90","article-title":"Efficacy of orlistat in non-alcoholic fatty liver disease: A systematic review and meta-analysis","volume":"9","author":"Wang","year":"2018","unstructured":"117 Wang H, Wang L, Cheng Y, Xia Z, Liao Y, Cao J. Efficacy of orlistat in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Biomed Rep. 2018;9(1):90-6. doi: 10.3892\/br.2018.1100","journal-title":"Biomed Rep"},{"issue":"6","key":"key20231207093321_B118","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.diabet.2019.12.007","article-title":"Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials","volume":"46","author":"Mantovani","year":"2020","unstructured":"118 Mantovani A, Byrne CD, Scorletti E, Mantzoros CS, Targher G. Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials. Diabetes Metab. 2020;46(6):427-41. doi: 10.1016\/j.diabet.2019.12.007","journal-title":"Diabetes Metab"},{"key":"key20231207093321_B119","doi-asserted-by":"crossref","first-page":"622589","DOI":"10.3389\/fendo.2020.622589","article-title":"Comparison of the Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Metabolic Associated Fatty Liver Disease: Updated Systematic Review and Meta-Analysis","volume":"11","author":"Dai","year":"2020","unstructured":"119 Dai Y, He H, Li S, Yang L, Wang X, Liu Z, et al. Comparison of the Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Metabolic Associated Fatty Liver Disease: Updated Systematic Review and Meta-Analysis. Front Endocrinol (Lausanne). 2020;11:622589. doi: 10.3389\/fendo.2020.622589","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"key20231207093321_B120","doi-asserted-by":"crossref","DOI":"10.3390\/metabo11020073","article-title":"Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials","volume":"11","author":"Mantovani","year":"2021","unstructured":"120 Mantovani A, Petracca G, Beatrice G, Csermely A, Lonardo A, Targher G. Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials. Metabolites. 2021;11(2). doi: 10.3390\/metabo11020073","journal-title":"Metabolites"},{"issue":"6","key":"key20231207093321_B121","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.2337\/dc19-1892","article-title":"Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes","volume":"43","author":"Hartman","year":"2020","unstructured":"121 Hartman ML, Sanyal AJ, Loomba R, Wilson JM, Nikooienejad A, Bray R, et al. Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes. Diabetes Care. 2020;43(6):1352-5. doi: 10.2337\/dc19-1892.","journal-title":"Diabetes Care"},{"issue":"2","key":"key20231207093321_B122","doi-asserted-by":"crossref","first-page":"114","DOI":"10.4239\/wjd.v10.i2.114","article-title":"SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A systematic review","volume":"10","author":"Raj","year":"2019","unstructured":"122 Raj H, Durgia H, Palui R, Kamalanathan S, Selvarajan S, Kar SS, et al. SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A systematic review. World J Diabetes. 2019;10(2):114-32. doi: 10.4239\/wjd.v10.i2.114","journal-title":"World J Diabetes"},{"issue":"6","key":"key20231207093321_B123","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.3413","article-title":"Effects of sodium-glucose co-transporter 2 inhibitors on liver parameters and steatosis: A meta-analysis of randomized clinical trials","volume":"37","author":"Coelho","year":"2021","unstructured":"123 Coelho FDS, Borges-Canha M, von Hafe M, Neves JS, Vale C, Leite AR, et al. Effects of sodium-glucose co-transporter 2 inhibitors on liver parameters and steatosis: A meta-analysis of randomized clinical trials. Diabetes Metab Res Rev. 2021;37(6):e3413. doi: 10.1002\/dmrr.3413","journal-title":"Diabetes Metab Res Rev"},{"issue":"5","key":"key20231207093321_B124","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/jamainternmed.2016.9607","article-title":"Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis","volume":"177","author":"Musso","year":"2017","unstructured":"124 Musso G, Cassader M, Paschetta E, Gambino R. Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis. JAMA Intern Med. 2017;177(5):633-40. doi: 10.1001\/jamainternmed.2016.9607","journal-title":"JAMA Intern Med"},{"issue":"4","key":"key20231207093321_B125","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1111\/dom.14304","article-title":"Pioglitazone and bariatric surgery are the most effective treatments for non-alcoholic steatohepatitis: A hierarchical network meta-analysis","volume":"23","author":"Panunzi","year":"2021","unstructured":"125 Panunzi S, Maltese S, Verrastro O, Labbate L, De Gaetano A, Pompili M, et al. Pioglitazone and bariatric surgery are the most effective treatments for non-alcoholic steatohepatitis: A hierarchical network meta-analysis. Diabetes Obes Metab. 2021;23(4):980-90. doi: 10.1111\/dom.14304","journal-title":"Diabetes Obes Metab"},{"issue":"18","key":"key20231207093321_B126","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","unstructured":"126 Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362(18):1675-85. doi: 10.1056\/NEJMoa0907929","journal-title":"N Engl J Med"},{"issue":"2","key":"key20231207093321_B127","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/hep.30368","article-title":"Vitamin E Improves Transplant-Free Survival and Hepatic Decompensation Among Patients With Nonalcoholic Steatohepatitis and Advanced Fibrosis","volume":"71","author":"Vilar-Gomez","year":"2020","unstructured":"127 Vilar-Gomez E, Vuppalanchi R, Gawrieh S, Ghabril M, Saxena R, Cummings OW, et al. Vitamin E Improves Transplant-Free Survival and Hepatic Decompensation Among Patients With Nonalcoholic Steatohepatitis and Advanced Fibrosis. Hepatology. 2020;71(2):495-509. doi: 10.1002\/hep.30368","journal-title":"Hepatology"},{"issue":"6","key":"key20231207093321_B128","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.cgh.2018.10.017","article-title":"Complete Resolution of Nonalcoholic Fatty Liver Disease After Bariatric Surgery: A Systematic Review and Meta-analysis","volume":"17","author":"Lee","year":"2019","unstructured":"128 Lee Y, Doumouras AG, Yu J, Brar K, Banfield L, Gmora S, et al. Complete Resolution of Nonalcoholic Fatty Liver Disease After Bariatric Surgery: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2019;17(6):1040-60.e11. doi: 10.1016\/j.cgh.2018.10.017","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"key20231207093321_B129","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1053\/j.gastro.2020.06.006","article-title":"Bariatric Surgery Provides Long-term Resolution of Nonalcoholic Steatohepatitis and Regression of Fibrosis","volume":"159","author":"Lassailly","year":"2020","unstructured":"129 Lassailly G, Caiazzo R, Ntandja-Wandji LC, Gnemmi V, Baud G, Verkindt H, et al. Bariatric Surgery Provides Long-term Resolution of Nonalcoholic Steatohepatitis and Regression of Fibrosis. Gastroenterology. 2020;159(4):1290-301.e5. doi: 10.1053\/j.gastro.2020.06.006","journal-title":"Gastroenterology"},{"issue":"20","key":"key20231207093321_B130","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1001\/jama.2021.19569","article-title":"Association of Bariatric Surgery With Major Adverse Liver and Cardiovascular Outcomes in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis","volume":"326","author":"Aminian","year":"2021","unstructured":"130 Aminian A, Al-Kurd A, Wilson R, Bena J, Fayazzadeh H, Singh T, et al. Association of Bariatric Surgery With Major Adverse Liver and Cardiovascular Outcomes in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis. JAMA. 2021;326(20):2031-42. doi: 10.1001\/jama.2021.19569","journal-title":"JAMA"},{"issue":"3","key":"key20231207093321_B131","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.soard.2020.11.004","article-title":"Safety of metabolic and bariatric surgery in obese patients with liver cirrhosis: a systematic review and meta-analysis","volume":"17","author":"Agarwal","year":"2021","unstructured":"131 Agarwal L, Sahu AK, Baksi A, Agarwal A, Aggarwal S. Safety of metabolic and bariatric surgery in obese patients with liver cirrhosis: a systematic review and meta-analysis. Surg Obes Relat Dis. 2021;17(3):525-37. doi: 10.1016\/j.soard.2020.11.004","journal-title":"Surg Obes Relat Dis"},{"issue":"11","key":"key20231207093321_B132","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.14309\/ajg.0000000000000911","article-title":"Improving Outcomes of Bariatric Surgery in Patients With Cirrhosis in the United States: A Nationwide Assessment","volume":"115","author":"Are","year":"2020","unstructured":"132 Are VS, Knapp SM, Banerjee A, Shamseddeen H, Ghabril M, Orman E, et al. Improving Outcomes of Bariatric Surgery in Patients With Cirrhosis in the United States: A Nationwide Assessment. Am J Gastroenterol. 2020;115(11):1849-56. doi: 10.14309\/ajg.0000000000000911","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"key20231207093321_B133","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1007\/s11695-021-05412-y","article-title":"Gastric Bypass Compared with Sleeve Gastrectomy for Nonalcoholic Fatty Liver Disease: a Systematic Review and Meta-analysis","volume":"31","author":"de Brito","year":"2021","unstructured":"133 de Brito ESMB, Tustumi F, de Miranda Neto AA, Dantas ACB, Santo MA, Cecconello I. Gastric Bypass Compared with Sleeve Gastrectomy for Nonalcoholic Fatty Liver Disease: a Systematic Review and Meta-analysis. Obes Surg. 2021;31(6):2762-72. doi: 10.1007\/s11695-021-05412-y","journal-title":"Obes Surg"},{"issue":"8","key":"key20231207093321_B134","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1007\/s11695-015-1727-2","article-title":"A Systematic Review of Bariatric Surgery in Patients with Liver Cirrhosis","volume":"25","author":"Jan","year":"2015","unstructured":"134 Jan A, Narwaria M, Mahawar KK. A Systematic Review of Bariatric Surgery in Patients with Liver Cirrhosis. Obes Surg. 2015;25(8):1518-26. doi: 10.1007\/s11695-015-1727-2","journal-title":"Obes Surg"},{"issue":"3","key":"key20231207093321_B135","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1093\/gastro\/goaa057","article-title":"Bariatric surgery proves long-term benefit in patients with cirrhosis","volume":"9","author":"Izzy","year":"2021","unstructured":"135 Izzy M, Angirekula M, Abu Dayyeh BK, Bazerbachi F, Watt KD. Bariatric surgery proves long-term benefit in patients with cirrhosis. Gastroenterol Rep (Oxf). 2021;9(3):252-6. doi: 10.1093\/gastro\/goaa057","journal-title":"Gastroenterol Rep (Oxf)"},{"issue":"4","key":"key20231207093321_B136","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.gie.2012.05.023","article-title":"Intragastric balloon significantly improves nonalcoholic fatty liver disease activity score in obese patients with nonalcoholic steatohepatitis: a pilot study","volume":"76","author":"Lee","year":"2012","unstructured":"136 Lee YM, Low HC, Lim LG, Dan YY, Aung MO, Cheng CL, et al. Intragastric balloon significantly improves nonalcoholic fatty liver disease activity score in obese patients with nonalcoholic steatohepatitis: a pilot study. Gastrointest Endosc. 2012;76(4):756-60. doi: 10.1016\/j.gie.2012.05.023.","journal-title":"Gastrointest Endosc"},{"issue":"1","key":"key20231207093321_B137","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.cgh.2020.04.068","article-title":"Intragastric Balloon Placement Induces Significant Metabolic and Histologic Improvement in Patients With Nonalcoholic Steatohepatitis","volume":"19","author":"Bazerbachi","year":"2021","unstructured":"137 Bazerbachi F, Vargas EJ, Rizk M, Maselli DB, Mounajjed T, Venkatesh SK, et al. Intragastric Balloon Placement Induces Significant Metabolic and Histologic Improvement in Patients With Nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol. 2021;19(1):146-154.e4. doi: 10.1016\/j.cgh.2020.04.068.","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Archives of Endocrinology and Metabolism"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T14:34:59Z","timestamp":1701959699000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aem-sbem.com\/article\/brazilian-evidence-based-guideline-for-screening-diagnosis-treatment-and-follow-up-of-metabolic-dysfunction-associated-steatotic-liver-disease-masld-in-adult-individuals-with-overweight-or-obesit\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":137,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12,7]]}},"alternative-id":["10.20945\/2359-4292-2023-0123"],"URL":"https:\/\/doi.org\/10.20945\/2359-4292-2023-0123","relation":{},"ISSN":["2359-3997","2359-4292"],"issn-type":[{"value":"2359-3997","type":"print"},{"value":"2359-4292","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023]]},"article-number":"e230123"}}